Neurocrine Biosciences Inc. (NBIX)

96.41
NASDAQ : Health Technology
Prev Close 94.13
Day Low/High 93.39 / 97.64
52 Wk Low/High 64.72 / 126.98
Avg Volume 641.50K
Exchange NASDAQ
Shares Outstanding 91.58M
Market Cap 8.62B
EPS 0.20
P/E Ratio 500.00
Div & Yield N.A. (N.A)
Neurocrine Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Presents At Deutsche Bank 37th Annual Health Care Conference (Transcript)

Neurocrine Biosciences' CEO Presents At Deutsche Bank 37th Annual Health Care Conference (Transcript)

Neurocrine Biosciences' CEO Presents at Deutsche Bank 37th Annual Health Care Conference (Transcript)

Neurocrine Biosciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Reviews Phase II Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia (Transcript)

Neurocrine Biosciences' CEO Reviews Phase II Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia (Transcript)

Neurocrine Biosciences' CEO Reviews Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia (Transcript)

Neurocrine Stock Falls On Unusually High Volume (NBIX)

Neurocrine Stock Falls On Unusually High Volume (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) is trading at unusually high volume Tuesday with 1.5 million shares changing hands. It is currently at 4.1 times its average daily volume and trading down 83 cents (-9.2%).

Apollo, Opnext: After-Hours Trading (Update 1)

Apollo, Opnext: After-Hours Trading (Update 1)

These stocks attracted trading interest in Monday's extended session.

Neurocrine Biosciences' CEO Presents At 30th Annual JPMorgan Global Healthcare Conference - Conference Call Transcript

Neurocrine Biosciences' CEO Presents At 30th Annual JPMorgan Global Healthcare Conference - Conference Call Transcript

Neurocrine Biosciences' CEO Presents at 30th Annual JPMorgan Global Healthcare Conference - Conference Call Transcript

Neurocrine Biosciences' CEO Citi 2012 Global Health Care Conference (Transcript)

Neurocrine Biosciences' CEO Citi 2012 Global Health Care Conference (Transcript)

Neurocrine Biosciences' CEO Citi 2012 Global Health Care Conference (Transcript)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been downgraded by TheStreet Ratings from from a buy to hold.

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been upgraded by TheStreet Ratings from a hold to buy.

Neurocrine Stock Falls On Unusually High Volume (NBIX)

Neurocrine Stock Falls On Unusually High Volume (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) is trading at unusually high volume Thursday with 1.5 million shares changing hands. It is currently at four times its average daily volume and trading down 72 cents (-7.7%).

Neurocrine Biosciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Neurocrine Stock Hits New 52-Week High (NBIX)

Neurocrine Stock Hits New 52-Week High (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) hit a new 52-week high Monday as it is currently trading at $8.95, above its previous 52-week high of $8.92 with 217,378 shares traded as of 10:43 a.m. ET. Average volume has been 364,900 shares over the past 30 days.

Neurocrine Stock Falls On Unusually High Volume (NBIX)

Neurocrine Stock Falls On Unusually High Volume (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) is trading at unusually high volume Thursday with 1.3 million shares changing hands. It is currently at 4.6 times its average daily volume and trading down 47 cents (-5.4%).

Neurocrine Stock Hits New 52-Week High (NBIX)

Neurocrine Stock Hits New 52-Week High (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) hit a new 52-week high Thursday as it is currently trading at $8.62, above its previous 52-week high of $8.60 with 64,263 shares traded as of 11:33 a.m. ET. Average volume has been 305,900 shares over the past 30 days.

Neurocrine Biosciences Presentation At 2011 Credit Suisse Annual Health Care Conference - Conference Call Transcript

Neurocrine Biosciences Presentation At 2011 Credit Suisse Annual Health Care Conference - Conference Call Transcript

Neurocrine Biosciences Presentation at 2011 Credit Suisse Annual Health Care Conference - Conference Call Transcript

Neurocrine Biosciences' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q3 2011 Results - Earnings Call Transcript

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look poised to break out and trade higher from current levels

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been downgraded by TheStreet Ratings from from a buy to hold.

Neurocrine Biosciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Neurocrine Biosciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been upgraded by TheStreet Ratings from a hold to buy.

Neurocrine Rises On Unusually High Volume (NBIX)

Neurocrine Rises On Unusually High Volume (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at four times its average daily volume and trading up 79 cents (+10.7%).

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been downgraded by TheStreet Ratings from from a buy to hold.

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences Inc. Stock Upgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been upgraded by TheStreet Ratings from a hold to buy.

Neurocrine Biosciences, Inc. CEO Discusses Q1 2011 Results - Earnings Call Transcript

Neurocrine Biosciences, Inc. CEO Discusses Q1 2011 Results - Earnings Call Transcript

Neurocrine Biosciences, Inc. CEO Discusses Q1 2011 Results - Earnings Call Transcript

Neurocrine Biosciences Inc. Stock Upgraded By TheStreet Ratings (NBIX)

Neurocrine Biosciences Inc. Stock Upgraded By TheStreet Ratings (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been upgraded by TheStreet Ratings from a sell to hold.

Neurocrine Biosciences CEO Discusses Q4 2010 Results - Earnings Call Transcript

Neurocrine Biosciences CEO Discusses Q4 2010 Results - Earnings Call Transcript

Neurocrine Biosciences CEO Discusses Q4 2010 Results - Earnings Call Transcript

Best Biotech CEO of 2010 Is...

Best Biotech CEO of 2010 Is...

TheStreet's readers picked Dendreon's Mitch Gold as the best biotech CEO of the year.

Biotech's Brighter Corners

Biotech's Brighter Corners

Speculative opportunities abound in the small- and mid-cap universe, but only for aggressive market players.

Vote for the Best Biotech CEO of 2010

Vote for the Best Biotech CEO of 2010

Readers will decide who takes home the award for the Best Biotech CEO of 2010. Vote now!

TheStreet Quant Rating: C+ (Hold)